Tags : Innovate Biopharmaceuticals

Innovate Initiates its Dosing For P-III CeD LA 3001 Trial

Shots: The P-III study involves assessing of larazotide acetate as an adjuvant therapy vs PBO in patients with celiac disease who still experience symptoms despite being on a gluten-free diet Innovate marks to be the first company in patient dosing in P-III celiac disease. Larazotide has met 1EPs in P-IIb efficacy clinical trial enrolling 342 […]Read More